Australia is eagerly anticipating the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist , representing a potential advance in weight loss . Early clinical trials have demonstrated impressive https://izaakcxtp291258.tribunablog.com/emerging-medication-in-australia-a-new-solution-for-obesity-management-58567914